Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer (NSCLC) Clinical Trial
Official title:
Analysis of the Incidence of Expression of Tumor Antigens MAGE-A3, MAGE-C2, NY-ESO-1, LAGE-1, WT1 and PRAME in Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer in Asiatic Patients
This study aims to investigate the expression of Melanoma-associated antigen 3 (MAGE-A3), Melanoma-associated antigen C2 (MAGE-C2), New York esophageal squamous cell carcinoma 1 (NY-ESO-1), L antigen family member 1 (LAGE-1), Wilms' tumor gene (WT1) and PRAME (PReferentially expressed Antigen of MElanoma) tumor antigens in a large number of pathologically proven stage I, II and III NSCLC samples of Asiatic patients.
This study will be based upon the analysis of samples and patient-related data already
available at the various investigation sites. There will be no study treatment and no
study-specific procedure carried out on the patients.
Clinical data collected will include patient demographics (age, gender), Tumor, Node,
Metastasis (staging system) [TNM stage], histopathologic description and the patient smoker
status. Strict anonymity of patient data will be maintained.
This retrospective study is based upon the analysis of archived formalin-fixed
paraffin-embedded tissue samples and patient-related data already available at the
investigational site.
;
Observational Model: Cohort, Time Perspective: Retrospective